DE60105322D1 - Wässerige zusammensetzung enthaltend amphotericin b - Google Patents

Wässerige zusammensetzung enthaltend amphotericin b

Info

Publication number
DE60105322D1
DE60105322D1 DE60105322T DE60105322T DE60105322D1 DE 60105322 D1 DE60105322 D1 DE 60105322D1 DE 60105322 T DE60105322 T DE 60105322T DE 60105322 T DE60105322 T DE 60105322T DE 60105322 D1 DE60105322 D1 DE 60105322D1
Authority
DE
Germany
Prior art keywords
compositions
amphotericin
composition containing
aqueous composition
containing amphotericin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60105322T
Other languages
English (en)
Other versions
DE60105322T2 (de
Inventor
Srikanth Pai
Sangeeta Rivankar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bharat Serums and Vaccines Ltd
Original Assignee
Bharat Serums and Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Serums and Vaccines Ltd filed Critical Bharat Serums and Vaccines Ltd
Application granted granted Critical
Publication of DE60105322D1 publication Critical patent/DE60105322D1/de
Publication of DE60105322T2 publication Critical patent/DE60105322T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
DE60105322T 2001-03-01 2001-03-16 Wässerige zusammensetzung enthaltend amphotericin b Expired - Lifetime DE60105322T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
INMU02001217 2001-03-01
IN217MU2001 IN188924B (de) 2001-03-01 2001-03-01
PCT/IN2001/000040 WO2002069983A1 (en) 2001-03-01 2001-03-16 Amphotericin b aqueous composition

Publications (2)

Publication Number Publication Date
DE60105322D1 true DE60105322D1 (de) 2004-10-07
DE60105322T2 DE60105322T2 (de) 2005-09-15

Family

ID=11097223

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60105322T Expired - Lifetime DE60105322T2 (de) 2001-03-01 2001-03-16 Wässerige zusammensetzung enthaltend amphotericin b

Country Status (23)

Country Link
US (1) US20040137049A1 (de)
EP (1) EP1368041B1 (de)
JP (1) JP2004523566A (de)
KR (1) KR100810067B1 (de)
CN (1) CN1255114C (de)
AT (1) ATE274913T1 (de)
AU (1) AU2001250643B2 (de)
BG (1) BG108188A (de)
BR (1) BR0116922A (de)
CA (1) CA2438847A1 (de)
CZ (1) CZ20032264A3 (de)
DE (1) DE60105322T2 (de)
DK (1) DK1368041T3 (de)
EA (1) EA006241B1 (de)
ES (1) ES2227172T3 (de)
IN (1) IN188924B (de)
MX (1) MXPA03007777A (de)
NZ (1) NZ528281A (de)
PT (1) PT1368041E (de)
SK (1) SK10742003A3 (de)
WO (1) WO2002069983A1 (de)
YU (1) YU75403A (de)
ZA (1) ZA200307307B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
JP2006069929A (ja) * 2004-08-31 2006-03-16 Konica Minolta Medical & Graphic Inc 真菌症治療製剤およびその製造方法
EA200700440A1 (ru) * 2004-09-13 2008-02-28 Бхарат Сирумс Энд Вэксинс Лтд. Композиции стабильных эмульсий для внутривенного введения, имеющие защитную эффективность
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
CN100418536C (zh) * 2005-04-06 2008-09-17 河南省眼科研究所 一种用于眼科的抗真菌药物组合物
JP5143131B2 (ja) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド 浸透圧送出システムの二片構成内部チャネル型の流れモジュレータ
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
KR101629521B1 (ko) * 2010-03-16 2016-06-13 우석대학교 산학협력단 난용성 약물 가용화 및 생체막 투과증진을 위한 알코올성 수상을 내상으로 하는 리포좀, 리포좀 조성물 및 리포좀의 제조방법
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN102525921B (zh) * 2012-02-06 2013-08-07 西安力邦制药有限公司 2,2’,6,6’-四异丙基-4,4’-二联苯酚脂微球制剂及其制备方法
US9744191B2 (en) 2012-03-19 2017-08-29 Yale University Antimicrobial compositions and methods
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
EP3222324B1 (de) 2016-03-23 2020-05-13 Wayne State University Valproat als topische antimykotische behandlung
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (de) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel
CN108344811A (zh) * 2017-01-24 2018-07-31 北京泰德制药股份有限公司 一种注射用脂质体中有机溶剂残留的检测方法
CN108309955B (zh) * 2018-04-27 2020-06-02 武昌理工学院 一种聚明胶肽结合型紫杉醇纳米颗粒的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
US5616334A (en) * 1987-03-05 1997-04-01 The Liposome Company, Inc. Low toxicity drug-lipid systems
US5100662A (en) * 1989-08-23 1992-03-31 The Liposome Company, Inc. Steroidal liposomes exhibiting enhanced stability
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5580575A (en) * 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
JP3956402B2 (ja) * 1996-03-04 2007-08-08 日本油脂株式会社 アンホテリシンｂ運搬体
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use

Also Published As

Publication number Publication date
EA006241B1 (ru) 2005-10-27
KR100810067B1 (ko) 2008-03-05
ATE274913T1 (de) 2004-09-15
SK10742003A3 (sk) 2004-01-08
CN1255114C (zh) 2006-05-10
YU75403A (sh) 2006-05-25
CA2438847A1 (en) 2002-09-12
DE60105322T2 (de) 2005-09-15
EA200300948A1 (ru) 2004-04-29
CN1505519A (zh) 2004-06-16
ZA200307307B (en) 2004-04-20
NZ528281A (en) 2006-11-30
IN188924B (de) 2002-11-23
ES2227172T3 (es) 2005-04-01
AU2001250643B2 (en) 2007-03-22
BG108188A (bg) 2004-09-30
EP1368041A1 (de) 2003-12-10
US20040137049A1 (en) 2004-07-15
MXPA03007777A (es) 2003-12-08
BR0116922A (pt) 2004-04-27
PT1368041E (pt) 2005-01-31
DK1368041T3 (da) 2005-01-17
JP2004523566A (ja) 2004-08-05
KR20040018337A (ko) 2004-03-03
CZ20032264A3 (cs) 2003-12-17
WO2002069983A1 (en) 2002-09-12
EP1368041B1 (de) 2004-09-01

Similar Documents

Publication Publication Date Title
DE60105322D1 (de) Wässerige zusammensetzung enthaltend amphotericin b
CY1120462T1 (el) Τοπικες ανθελμινθικες κτηνιατρικες τυποποιησεις
WO2001092288A3 (en) Cobalamin compounds useful as antibiotic agents and as imaging agents
BR0112461A (pt) Composições que contém componentes terapeuticamente ativos tendo uma solubilidade aumentada
CY1105362T1 (el) Παραγωγα σουλφοναμιδιου, η παρασκευη τους και η εφαρμογη αυτων ως φαρμακα
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
SE0102315D0 (sv) Compounds
UA88463C2 (ru) Фармацевтическая композиция, которая содержит соединение 1, и процесс лечения вич-инфекции
CY1110664T1 (el) Ενδορινικες συνθεσετς
MY135850A (en) Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use
ATE386725T1 (de) Heterocyclylverbindungen
ES2186550A1 (es) Nuevos derivados de oxazolidinonas como antibacterianos.
NO20005497L (no) Heterocykliske derivater som inhiberer faktor Xa
MXPA04006041A (es) Antivirales de piridoquinoxalina.
HK1120794A1 (en) Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
WO2003090744A8 (en) Antibacterial compositions comprising metal phthalocyanine analogues
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
BRPI0519752A2 (pt) compostos peptÍdicos
CY1106711T1 (el) Υποκατεστημενα παραγωγα προπανο-1,3-διαμινης και η φαρμακευτικη χρηση τους
EP1411956B8 (de) Verwendung von übersulfatierten polysacchariden als hiv-hemmer
PT1181300E (pt) Derivados 6-o-carbamato de cetolido
UY27311A1 (es) Agentes antibacterianos
AR041235A1 (es) Composicion acuosa de amfotericina b
UA88325C2 (en) Phosphoindoles as hiv inhibitors

Legal Events

Date Code Title Description
8364 No opposition during term of opposition